 Anti-HIV Agents
"Anti-HIV Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents used to treat AIDS and/or stop the spread of the HIV infection. These do not include drugs used to treat symptoms or opportunistic infections associated with AIDS.
| Descriptor ID |
D019380
|
| MeSH Number(s) |
D27.505.954.122.388.077.088
|
| Concept/Terms |
Anti-HIV Agents- Anti-HIV Agents
- Agents, Anti-HIV
- Anti HIV Agents
- Anti-AIDS Agents
- Agents, Anti-AIDS
- Anti AIDS Agents
- Anti-HIV Drugs
- Anti HIV Drugs
- Drugs, Anti-HIV
- AIDS Drugs
- Drugs, AIDS
- Anti-AIDS Drugs
- Anti AIDS Drugs
- Drugs, Anti-AIDS
|
Below are MeSH descriptors whose meaning is more general than "Anti-HIV Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-HIV Agents".
This graph shows the total number of publications written about "Anti-HIV Agents" by people in this website by year, and whether "Anti-HIV Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1998 | 4 | 4 | 8 | | 1999 | 4 | 3 | 7 | | 2000 | 4 | 0 | 4 | | 2001 | 5 | 1 | 6 | | 2002 | 4 | 1 | 5 | | 2003 | 2 | 2 | 4 | | 2004 | 9 | 1 | 10 | | 2005 | 8 | 4 | 12 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 2 | 7 | | 2008 | 9 | 2 | 11 | | 2009 | 10 | 3 | 13 | | 2010 | 10 | 2 | 12 | | 2011 | 10 | 8 | 18 | | 2012 | 18 | 2 | 20 | | 2013 | 14 | 4 | 18 | | 2014 | 22 | 6 | 28 | | 2015 | 15 | 5 | 20 | | 2016 | 30 | 11 | 41 | | 2017 | 28 | 9 | 37 | | 2018 | 25 | 7 | 32 | | 2019 | 22 | 6 | 28 | | 2020 | 29 | 6 | 35 | | 2021 | 39 | 5 | 44 | | 2022 | 39 | 0 | 39 | | 2023 | 32 | 2 | 34 | | 2024 | 18 | 9 | 27 | | 2025 | 28 | 3 | 31 | | 2026 | 3 | 0 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Anti-HIV Agents" by people in Profiles.
-
Wamakima B, Diouf K, Modest A, Macharia A, Boikanyo K, Hanson SJ, Diseko M, Mabuta J, Rubgega F, Morroni C, Caniglia E, Jackson-Gibson M, Makhema J, Hofmeyr J, Zash R, Shapiro R, Luckett R. Pre-Eclampsia Rates in Women With and Without HIV in Modern ART Era in Botswana. J Acquir Immune Defic Syndr. 2026 Mar 01; 101(3):241-248.
-
Huynh D, Nikanjam M, Cunningham CK, McFarland EJ, Muresan P, Perlowski C, Yin DE, Moye J, Spiegel H, Gama L, Gaudinski M, Capparelli EV. Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants. J Antimicrob Chemother. 2026 Jan 19; 81(2).
-
Sun S, Nikanjam M, Mirochnick M, Powis KM, Eke AC, Stek A, Arora P, Cressey TR, Brooks KM, Best BM, Capparelli EV, Momper JD. Population Pharmacokinetics of Bictegravir During Pregnancy and Postpartum: Role of Adherence in Maintaining Therapeutic Exposure. J Clin Pharmacol. 2026 Jan; 66(1):e70134.
-
Miller SE, Dukes KA, Damato-MacPherson C, Psaros C, Scott NA, Taylor JL, Muroff J, Winter MR, Skiba LE, Lugo H, Cruz R, Ruiz-Mercado G, Crawford ND, Mayer KH, Assoumou SA. Pre-exposure prophylaxis (PrEP) and medications for opioid use disorder for persons who inject drugs: the CHORUS?+?randomized controlled trial study protocol. Addict Sci Clin Pract. 2025 Dec 25; 21(1):17.
-
Abuogi LL, Imran R, Limas A, Moor J, Leonard K, Pierce K, De La Garza AJ, Gallegos S, Duenas J, Littrell Z, Vyas P, Richards M, Straub D, McFarland EJ. Pilot outcomes of a telehealth model for youth PrEP (TelePrEP) among youth at risk for HIV in Colorado. HIV Res Clin Pract. 2025 Dec 31; 26(1):2588009.
-
Hawkins KL, Hojat LS, Hicks C, McLees MP, Rowan S, Burman WJ, Gardner EM. The "ART review": formalizing a process to document complex HIV treatment histories and to support treatment optimization. AIDS Care. 2025 Nov; 37(11):1883-1893.
-
Engel N, Sykes C, Schauer AP, Kashuba ADM, Anderson PL, Bushman LR, Cottrell ML. Interlaboratory comparison of a dried blood spot assay for antiretroviral adherence: implications for clinical application. J Antimicrob Chemother. 2025 Oct 03; 80(10):2727-2731.
-
Hampanda K, Bolt M, Nayame L, Sehrt M, Thorne J, Hamoonga TE, Harrison MS, Pintye J, Amstutz A, Abuogi LL, Mweemba O. HIV Risk and Intention to Use HIV Pre-exposure Prophylaxis Among Sexually Active Female University Students in Zambia: A Cross-Sectional Survey to Understand Influential Factors. AIDS Patient Care STDS. 2025 Oct; 39(10):418-426.
-
Edwards KA, Long D, Jones KF, Durr AL, Farel CE, Liebschutz JM, Bair MJ, Agil D, Napravnik S, Browne L, Johnson B, Thomas T, Burkholder G, Clay OJ, Demonte W, Orris SM, Johnson MO, Merlin J. The Skills to Manage Pain Randomized Trial: Results of Antiretroviral Therapy Adherence, HIV Primary Care Retention, and Virologic Suppression Outcomes. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):180-185.
-
Anderson PL, Coppinger C, Cottrell ML, Marzinke MA. Recommendations for Interpreting Intraerythrocytic Tenofovir Diphosphate and Emtricitabine Triphosphate for HIV-1 Preexposure Prophylaxis Adherence Assessment. J Acquir Immune Defic Syndr. 2025 Oct 01; 100(2):162-169.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|